Precipio (PRPO) AI Stock Analysis

• Market Cap: $23.34M
• Dividend Yield: N/A
• Average Volume (3M): 8.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: 27.05%
• EPS Growth: 55.03%
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.05
• Shares Outstanding: 1,619,584
• 10 Day Avg. Volume: 11,711
• 30 Day Avg. Volume: 8,298
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 0.99
• Enterprise Value/Gross Profit: 2.26
• Enterprise Value/Ebitda: -10.18
• 1Y Price Target: $15.00
• Price Target Upside: -1.70% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 60 Neutral
• Price Target: $15.00 ▼(-1.70% Downside)

Precipio's overall score is driven by strong earnings call insights and positive technical indicators. However, financial performance and valuation concerns, including ongoing losses and negative cash flow, weigh down the score. Recent corporate advancements provide a positive outlook, but profitability improvements are crucial for a higher score.

Precipio Business Overview & Revenue Model

Company Description

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

How the Company Makes Money

Precipio generates revenue through multiple streams, including the provision of its molecular diagnostic testing services, which are billed to healthcare providers and patients. The company also earns income from its proprietary technology platform, which offers software solutions for data analysis and reporting in oncology. Key revenue streams include sales from diagnostic tests, licensing agreements for its technology, and partnerships with healthcare institutions that utilize its services. Additionally, collaborations with pharmaceutical companies for clinical trial support and companion diagnostics further contribute to its earnings, enhancing the company's financial stability.

Precipio Financial Statement Overview

Summary

Precipio is showing revenue growth and improved cost management, yet faces profitability challenges with negative margins. The balance sheet is stable with strong equity and low debt levels, providing a solid foundation for future growth. Cash flow improvements are promising, but the company needs to achieve profitability to enhance financial health further.

Income Statement

Precipio has shown a consistent growth in revenue, with a notable increase of 21.2% in the TTM (Trailing-Twelve-Months) compared to the previous year. However, the company is still operating at a loss with a negative net profit margin of -16.0% in the TTM. The gross profit margin improved to 43.8% in the TTM, indicating better cost management. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet reflects a stable equity base with an equity ratio of 65.8% in the TTM, signaling financial stability. The debt-to-equity ratio is low at 0.18, indicating limited financial leverage. However, return on equity remains negative due to ongoing losses, which is a concern for profitability.

Cash Flow

Precipio's cash flow shows improvement with positive operating cash flow in the TTM, representing a significant recovery. Free cash flow also turned positive, indicating better cash management. However, both operating cash flow to net income and free cash flow to net income ratios are not optimal due to negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.36M	15.96M	15.20M	9.41M	8.85M	6.09M
Gross Profit	8.48M	7.56M	6.02M	2.51M	2.39M	1.15M
EBITDA	-1.88M	-2.70M	-4.32M	-10.65M	-7.05M	-8.77M
Net Income	-3.10M	-4.29M	-5.85M	-12.20M	-8.55M	-12.23M
Balance Sheet
Total Assets	17.79M	17.00M	18.10M	21.50M	30.44M	20.71M
Cash, Cash Equivalents and Short-Term Investments	1.02M	1.39M	1.50M	3.44M	11.67M	2.66M
Total Debt	2.23M	1.25M	1.12M	1.39M	1.43M	1.49M
Total Liabilities	6.09M	4.90M	3.67M	5.14M	5.83M	6.55M
Stockholders Equity	11.70M	12.09M	14.43M	16.30M	24.56M	14.13M
Cash Flow
Free Cash Flow	701.00K	216.00K	-3.69M	-8.00M	-7.26M	-7.58M
Operating Cash Flow	1.06M	439.00K	-3.56M	-7.72M	-6.58M	-7.43M
Investing Cash Flow	-361.00K	-223.00K	-126.00K	-277.00K	-682.00K	-96.00K
Financing Cash Flow	-460.00K	-329.00K	1.74M	-225.00K	16.27M	9.34M

Precipio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPO, the sentiment is Positive. The current price of 15.26 is above the 20-day moving average (MA) of 14.40, above the 50-day MA of 13.73, and above the 200-day MA of 8.63, indicating a bullish trend. The MACD of 0.24 indicates Positive momentum. The RSI at 63.94 is Neutral, neither overbought nor oversold. The STOCH value of 40.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRPO.

Precipio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	60 Neutral	$23.34M	―	-14.76%	―	27.05%	55.03%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
TRIB	48 Neutral	$26.54M	―	77.20%	―	-4.02%	-6.31%
BNGO	47 Neutral	$18.68M	―	-118.26%	―	-25.02%	85.08%
BIAF	47 Neutral	$7.18M	―	-1802.45%	―	4.99%	22.58%
INBS	46 Neutral	$13.14M	―	-186.64%	―	-1.90%	87.72%
DRIO	45 Neutral	$25.14M	―	-55.06%	―	41.79%	18.44%

Precipio Corporate Events

Precipio Unveils Advancements in AML Diagnostic Technology

On August 18, 2025, Precipio Inc released an updated investor presentation, highlighting its advancements in diagnostic technology, particularly for Acute Myeloid Leukemia (AML). The company’s rapid AML test significantly reduces diagnosis time, offering immediate treatment options and improving patient outcomes. Precipio’s innovative product development platform and profitable clinical lab business support its R&D efforts, addressing industry challenges such as diagnostic errors and delays, and enabling cost-effective solutions with high gross margins.

Precipio Announces Q2-2025 Shareholder Update Call

On July 31, 2025, Precipio, Inc. announced it will host a Q2-2025 Shareholder Update Call on August 14, 2025, at 5:00 PM ET. The call will provide updates on the company’s core businesses, reflecting its commitment to transparency and stakeholder engagement.

Precipio Holds Annual Stockholders Meeting, Approves Proposals

On June 17, 2025, Precipio, Inc. held its Annual Meeting of stockholders, where two key proposals were voted on and approved. The stockholders elected Ilan Danieli and David S. Cohen as Class I directors for terms expiring in 2028 and ratified the appointment of CBIZ CPAs, P.C. as the independent registered public accounting firm for the year ending December 31, 2025.